Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.32 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.32 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30444365 | 0.96 | PKM (0.34) | ALDH1A1HTTNPSR1KMT2ACRHBP | |
| SCHEMBL218350 | 0.91 | ALDH1A1 (0.40) | ALDH1A1HTTNPSR1KMT2ACRHBP | |
| SCHEMBL13901914 | 0.89 | PKM (0.33) | ALDH1A1HTTCRHBPCRHR2MCOLN3 | |
| SCHEMBL27258766 | 0.84 | — | — | |
| SCHEMBL11015180 | 0.83 | ALDH1A1 (0.36) | ALDH1A1HTTNPSR1KMT2APKM | |
| SCHEMBL15515078 | 0.83 | ALDH1A1 (0.36) | ALDH1A1HTTNPSR1KMT2AHSD11B1 | |
| SCHEMBL7481619 | 0.80 | ALDH1A1 (0.39) | ALDH1A1HTTNPSR1KMT2ACRHBP | |
| SCHEMBL1502471 | 0.79 | PKM (0.39) | ALDH1A1HTTNPSR1PKM | |
| SCHEMBL1374984 | 0.77 | CYP1A2 (0.34) | ALDH1A1PKMHSD11B1L3MBTL1 | |
| SCHEMBL15514504 | 0.77 | HSD11B1 (0.33) | ALDH1A1HTTNPSR1KMT2ACRHBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3263566-A1 | BICYCLO[3.2.1]OCTYL AMIDE DERIVATIVES AS ALLOSTERIC MODULATORS OF THE METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLU5 OR MGLUR5) FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) DISORDERS | H. Lundbeck A/S (DK) | 2018-01-03 | — | — | EP | disclosed |
| EP-3263566-A1 | BICYCLO[3.2.1]OCTYL AMIDE DERIVATIVES AS ALLOSTERIC MODULATORS OF THE METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLU5 OR MGLUR5) FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) DISORDERS | H. Lundbeck A/S (DK) | 2018-01-03 | — | — | EP | disclosed |
| US-20170217950-A1 | Bicyclo[3.2.1]Octyl Amide Derivatives and Uses of Same | H. LUNDBECK A/S (DK) | 2017-08-03 | — | — | US | disclosed |
| US-20170217950-A1 | Bicyclo[3.2.1]Octyl Amide Derivatives and Uses of Same | H. LUNDBECK A/S (DK) | 2017-08-03 | — | — | US | disclosed |
| US-20170217950-A1 | Bicyclo[3.2.1]Octyl Amide Derivatives and Uses of Same | H. LUNDBECK A/S (DK) | 2017-08-03 | — | — | US | disclosed |
| EP-2654422-B1 | Bicyclo[3.2.1]octyl amide derivatives as allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5 or mGluR5) for the treatment of central nervous system (CNS) disorders | H LUNDBECK AS (DK) | 2017-08-02 | — | — | EP | disclosed |
| EP-2654422-B1 | Bicyclo[3.2.1]octyl amide derivatives as allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5 or mGluR5) for the treatment of central nervous system (CNS) disorders | H LUNDBECK AS (DK) | 2017-08-02 | — | — | EP | disclosed |
| US-9656975-B2 | Bicyclo[3.2.1]octyl amide derivatives and uses of same | H. LUNDBECK A/S (DK) | 2017-05-23 | — | — | US | disclosed |
| US-9656975-B2 | Bicyclo[3.2.1]octyl amide derivatives and uses of same | H. LUNDBECK A/S (DK) | 2017-05-23 | — | — | US | disclosed |
| US-9656975-B2 | Bicyclo[3.2.1]octyl amide derivatives and uses of same | H. LUNDBECK A/S (DK) | 2017-05-23 | — | — | US | disclosed |
| US-8921370-B2 | Bicyclo[3.2.1]octyl amide derivatives and uses of same | H. LUNDBECK A/S (DK) | 2014-12-30 | — | — | US | disclosed |
| US-8921370-B2 | Bicyclo[3.2.1]octyl amide derivatives and uses of same | H. LUNDBECK A/S (DK) | 2014-12-30 | — | — | US | disclosed |
| EP-2654422-A1 | BICYCLO[3.2.1]OCTYL AMIDE DERIVATIVES AND USES OF SAME | H. Lundbeck A/S (DK) | 2013-10-30 | — | — | EP | disclosed |
| EP-2654422-A1 | BICYCLO[3.2.1]OCTYL AMIDE DERIVATIVES AND USES OF SAME | H. Lundbeck A/S (DK) | 2013-10-30 | — | — | EP | disclosed |
| CN-103369961-A | Bicyclo [3.2.1] octylamide derivatives and uses thereof | LUNDBECK & AMP | 2013-10-23 | — | — | CN | disclosed |
| CN-103369961-A | Bicyclo [3.2.1] octylamide derivatives and uses thereof | LUNDBECK & AMP | 2013-10-23 | — | — | CN | disclosed |
| US-20120190686-A1 | BICYCLO[3.2.1]OCTYL AMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2012-07-26 | — | — | US | disclosed |
| US-20120190686-A1 | BICYCLO[3.2.1]OCTYL AMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2012-07-26 | — | — | US | disclosed |
| WO-2012088365-A1 | BICYCLO[3.2.1]OCTYL AMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012088365-A1 | BICYCLO[3.2.1]OCTYL AMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217950-A1 | Bicyclo[3.2.1]Octyl Amide Derivatives and Uses of Same | SLC10A1, CLIC1, ABCB11 | ALDH1A1 363/4885HTT 3404/4885NPSR1 1072/4885 |
| US-20120190686-A1 | BICYCLO[3.2.1]OCTYL AMIDE DERIVATIVES AND USES OF SAME | SLC10A1, CLIC1, ABCB11 | ALDH1A1 363/4885HTT 3404/4885NPSR1 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.